key: cord-0275384-sqwn1zmc
authors: Namba, S.; Konuma, T.; Wu, K.-H.; Zhou, W.; Global Biobank Meta-analysis Initiative,; Okada, Y.
title: A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis
date: 2021-12-05
journal: nan
DOI: 10.1101/2021.12.03.21267280
sha: ea208c60d3a1add4960de2a194124cf4ece07d58
doc_id: 275384
cord_uid: sqwn1zmc

Genomics-driven drug discovery is indispensable for accelerating the development of novel therapeutic targets. However, the drug discovery framework based on evidence from genome-wide association studies (GWAS) has not been established, especially for cross-population GWAS meta-analysis. Here, we introduce a practical guideline for genomics-driven drug discovery for cross-population meta-analysis, as lessons from the Global Biobank Meta-analysis Initiative (GBMI). Our drug discovery framework encompassed three methodologies and was applied to the 13 common diseases targeted by GBMI (N mean = 1,329,242). First, we evaluated the overlap enrichment between disease risk genes and the drug-target genes of the disease-relevant medication categories. An omnibus approach integrating the four gene prioritization tools yielded twice the enrichment in the disease-relevant medication categories compared with any single tool, and identified drugs with approved indications for asthma, gout, and venous thromboembolism. Second, we performed an endophenotype Mendelian randomization analysis using protein quantitative trait loci as instrumental variables. After the application of quality controls, including a colocalization analysis, significant causal relationships were estimated for 18 protein-disease pairs, including MAP2K inhibitors for heart failure. Third, we conducted an in silico screening for negative correlations between genetically determined disease case-control gene expression profiles and compound-regulated ones. Significant negative correlations were observed for 31 compound-disease pairs, including a histone deacetylase inhibitor for asthma. Integration of the three methodologies provided a comprehensive catalog of candidate drugs for repositioning, nominating promising drug candidates targeting the genes involved in the coagulation process for venous thromboembolism. Our study highlighted key factors for successful genomics-driven drug discovery using cross-population meta-analysis.

including MAP2K inhibitors for heart failure. Third, we conducted an in silico screening for 48 negative correlations between genetically determined disease case-control gene expression 49 profiles and compound-regulated ones. Significant negative correlations were observed for 50 31 compound-disease pairs, including a histone deacetylase inhibitor for asthma. Integration 51 of the three methodologies provided a comprehensive catalog of candidate drugs for 52 repositioning, nominating promising drug candidates targeting the genes involved in the 53 coagulation process for venous thromboembolism. Our study highlighted key factors for 54 successful genomics-driven drug discovery using cross-population meta-analysis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint Introduction 60 Efficient screening of novel therapeutic targets is an essential process to accelerate drug 61 discovery. Despite the enormous effort to develop novel drugs, the overall success rate of 62 clinical application has been decreasing because of the considerable increase in both the 63 cost and the duration 1 . Genomics-driven drug discovery is one of the promising solutions, as 64 drug targets with human genetic support are more likely to be successful in clinical sizes are population-specific especially in functionally important regions 11 . Therefore, a 81 specialized drug discovery framework is required for cross-population GWAS meta-analyses. 82 In this study, we introduce a practical guideline as lessons from the Global Biobank is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint 6 hospital-based biobanks), including up to 1.8 million participants from the 18 biobanks in four 86 continents (341,000 East Asians (EAS); 31,000 Central and South Asians; 33,000 Africans; 87 18,000 Admixed Americans; 1,600 Middle Easterners; 156,000 Finns; and 1,220,000 Non- 88 Finnish Europeans [NFE] ), serving as a gold-standard cross-population GWAS meta-analysis. 89 We propose a cross-population drug discovery framework comprising three major compounds that might correct disease-related alterations in gene expression. 97 We applied our framework to the 13 common and relatively rare disease GWAS included stroke, uterine cancer (UtC), acute appendicitis (AcApp), and hypertrophic cardiomyopathy 102 (HCM). Our pipeline identified 144 drug/compound-disease pairs and nominated a 103 comprehensive catalog of candidate drugs for repositioning. Our study demonstrates that the 104 integration of the candidate drugs and compounds screened using each methodology 105 enables in-depth drug discovery. In particular, drug discovery captured plausible drug targets 106 targeting coagulation-related genes for VTE. Our results demonstrated the utility of 107 genomics-driven drug discovery using a cross-population GWAS meta-analysis and suggest 108 key factors for successful drug discovery. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint

Overview of the genomics-driven drug discovery framework 112 Various types of omics-based approaches have been proposed for novel target identification 113 and drug repositioning from GWAS summary statistics 6 . Each type of omics data necessitates 114 specialized methodologies. Further, no simple method has emerged that enables the 115 interpretation of genomics-discoveries for drug discovery. Therefore, our framework was is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint 10 146 Overlap enrichment of disease risk genes in medication categories 147 The first component prioritized disease risk genes by calculating gene scores or P-values, 148 and examined whether the prioritized genes are enriched in drug-target genes of specific 149 medication categories. There exist several gene prioritization tools, although it remains 150 unclear which tool is best optimized for drug discovery. Therefore, we evaluated four tools in Figure 1D) . We replicated the analyses using ICD-10 and 169 observed a similar pattern of enrichment as ATC codes (Supplementary Figure 2) . 170 Next, we summarized the overlap enrichment into disease-relevant and disease- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. Table 1) , and showed a twice larger OR than did those of any single tool is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint 12 prioritized for VTE were involved in the coagulation cascade, and four of them (F2, F10, FGA, 198 and PROC) were the approved drug targets for VTE. The prioritized genes for asthma were 199 also enriched in antineoplastic and immunomodulating agents. Although the drugs in this 200 category have not been indicated for asthma, their target genes involved immune genes, 201 such as IL1R1, suggesting that the omnibus approach correctly prioritized genes related to 202 asthma. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint restricted IVs to those with low heterogeneity between studies and low pleiotropy between 212 proteins, whereas we used both cisand trans-pQTL to target a wide range of proteins, as 213 described previously 18 (Methods). We conducted an MR analysis using the 266 IVs 214 associated with the 229 drug-targeted proteins, to test the causal effects on the 13 diseases.

After applying multiple test corrections, 25 protein-disease pairs showed significant causality 216 (FDR < 0.05, Supplementary Table 2) . Twelve pairs were derived from cis-pQTL, whereas 217 the remaining ones were derived from trans-pQTL. 218 To protect against false positives from the results of the MR analysis, we applied two 219 quality-control metrics, i.e., colocalization analysis and concordance of directional effects.

The colocalization analysis was used to check whether two signals were equally distributed 221 on the local LD structure. Therefore, we used the GBMI GWAS of the NFE-specific meta- 222 analysis for MR and colocalization analysis, rather than the all-ancestry meta-analysis, to is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint 15 decomposed by SuSiE 34 . SuSiE detected three and two signals for the GWAS of VTE and 232 pQTL of F11, respectively, of which two signals were inferred to be colocalized. 233 Next, we assessed whether the inferred causal relationships were consistent with 234 clinical implications and experimental evidence. We found literature-based support of the 235 causal signs of the MR effect sizes for six protein-disease pairs (Supplementary Table 3) . 236 For example, lipoprotein(a) (LPA) for AAA and PDGFB for VTE have been reported to be 237 disease biomarkers 35, 36 . Similarly, ApoB-containing lipoproteins were associated with 238 angiotensin II-induced AAA in a mouse model 37 . In contrast, we found that the negative sign 239 of the MR effect size for PROC-VTE was not consistent with the knowledge that protein C, Table 3 ). These drugs included MAP2K inhibitors 246 for HF, which experimentally ameliorate cardiac hypertrophy and cardiomyopathy 42,43 .

Regarding the F11-VTE pair, an F11 inhibitor, Abelacimab, showed efficacy for the prevention 248 of VTE in a phase II trial 44 . In addition, as an agonist of PLAU for asthma, the urokinase-type 249 plasminogen activator was reported to reduce airway remodeling in a mouse model 45 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint Because a large sample size and population-specific LD structure are required for robust in 261 silico estimation of GReX by TWAS 9 , we restricted our analysis to the results of the 262 population-specific meta-analyses of EAS and NFE. An EAS-specific meta-analysis was not 263 performed in GBMI for three diseases, i.e., ThC, AAA, and AcApp, which were excluded. We 264 calculated correlation coefficients in the two populations separately and subsequently 265 combined them in a random-effect meta-analysis framework. We obtained 31 compound- 266 disease pairs with an FDR < 0.05 (Figure 4) . 267 The negative correlation tests can be applied even to compounds without known targets We further identified promising compounds with marginal significance (FDR < 0.1).

There were 123 unique compound-disease pairs with an FDR < 0.1, and mechanistic actions 277 were known for 72 compounds. The supporting literature was identified for the 26 compounds. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint Indacaterol (a beta-2 adrenergic receptor (ADRB2) agonist) and masatinib (a proto-oncogene is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint 20 Combining the three approaches for in-depth drug discovery 297 We summarized the representative drugs and their targets, which were prioritized through 298 the three drug discovery approaches, in Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint

Overlap enrichment in disease-relevant ATC codes Endophenotype MR Negative correlation tests The diseases are sorted in the decreasing order of the number of the genome-wide significant loci in GBMI GWAS. 1 We noted that the VTE GWAS was most successful in the screening of the drug targets: it 2 prioritized drugs corresponding to the eight drug-target genes and one compound in total 3 (Figure 5) . All drug targets but PDGFB were involved in the coagulation cascade. PDGFB 4 has been reported to induce the expression of a tissue factor that triggers the coagulation 5 cascade 54 , which underscores the strong enrichment of candidate drug targets in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint

In this study, we presented a practical framework that combined three approaches for in-15 depth genomics-driven drug discovery, and demonstrated its utility through application to the 16 GBMI GWAS meta-analysis. Each approach has specific advantages. By focusing on the 17 genes prioritized in the disease-relevant medication codes, we obtained a list of candidate is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 18,000 Admixed Americans; 1,600 Middle Easterners; 156,000 Finns; and 1,220,000 NFE) 7 . 69 We used the GBMI GWAS of 13 common diseases: asthma, POAG, gout, COPD, VTE, ThC, 70 AAA, HF, IPF, stroke, UtC, AcApp, and HCM. Although a GBMI GWAS was also conducted 71 for appendectomy, we excluded this trait because it was a procedure endpoint rather than a 72 disease.

Gene prioritization 75 We used four tools for gene prioritization from GWAS summary statistics, i.e., MAGMA, 76 DEPICT, Pi, and PoPS. We used the default settings, unless otherwise stated. Variants with 77 P-values < 1.0 × 10 -5 were used as input for DEPICT. We followed the original paper for the 78 setup of Pi 5 . Specifically, we used the lead variants with P < 5.0×10 -8 as input, eQTL in the interest 24 . Here, we used top-ranked genes, rather than pinpointed genes, to incorporate 84 multiple genes per locus for drug discovery. We used the summary statistics of the all-85 population GWAS meta-analyses as input and the European subset of the 1000 Genomes 86 Project (Phase 3) as a reference, given that more than half of the GBMI samples were NFE 7 . 87 We prioritized genes with conventional thresholds, i.e., FDR < 0.05 for MAGMA, and top 5% is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint and 10% of the genes with the highest gene scores. In addition, a Pi score > 1.5, 2.0, 2.5, 94 and 3.0 for Pi, and a PoPS score > 0, 0.5, 1.0, 1.5, and 2 for PoPS were also examined.

Enrichment analysis of drug indication categories 97 We used the list of prioritized genes as input to perform a series of Fisher's exact tests for 98 ATC or ICD-10 codes, to test the enrichment of drug-target genes in particular codes. We 99 used the drug-target database provided by GREP 14 , which was constructed by curating two is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint as the variants that were associated with no more than five proteins and did not show 117 heterogeneity in the five studies. When the lead variant of the pQTL was missing in the GBMI 118 GWAS summary statistics, we used a proxy variant with the largest R 2 , if the R 2 was larger 119 than 0.8. We checked the directionality of causal relationships using Steiger filtering 62 . MR 120 analyzes were performed using the "TwoSampleMR" R package 63 .

Colocalization analysis 123 To test colocalization in the presence of multiple causal variants, we applied coloc to the 124 signals decomposed by SuSiE 32 for each locus, including the variants located within ±500 125 kb of the lead variant (coloc + SuSiE). If SuSiE 34 did not converge in 100 iterations for either 126 pQTL or GBMI GWAS, we instead used coloc 33 . Coloc + SuSiE and coloc were performed 127 using their default parameters. The summary statistics were not publicly available for two 128 pQTL studies 30,31 ; therefore, we compared R 2 between the lead variants of the pQTL and the 129 GBMI GWAS for those studies. We considered that the signals of pQTL and GBMI GWAS 130 were colocalized if the maximum posterior probability of colocalization (i.e., PP.H4 for coloc 131 and coloc + SuSiE) was larger than 0.8, or the R 2 between the lead variants was larger than 132 0.8. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint 29 specific GWAS meta-analyses, separately. The correlation coefficients were combined by a 142 random-effect model using the R package "metacor." is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint 167 The authors declare no competing interests. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint

Clinical 171 development success rates for investigational drugs

The support of human genetic evidence for approved drug 174 indications

Are drug targets with genetic support twice 176 as likely to be approved? Revised estimates of the impact of genetic support for drug 177 mechanisms on the probability of drug approval

Evolocumab and Clinical Outcomes in Patients with 179

A genetics-led approach defines the drug target landscape of 30 181 immune-related traits

Advancing the use of genome-wide association studies 183 for drug repurposing

Global Biobank Meta-analysis Initiative: power genetic discovery for 185 human diseases with > 2.6 million samples across diverse ancestries

A cross-population atlas of genetic associations for 220 human 188 phenotypes

Opportunities and challenges for transcriptome-wide association 190 studies

The transferability of lipid loci across African

Population-specific causal disease effect sizes in functionally important 194 regions impacted by selection

Genetics of rheumatoid arthritis contributes to biology and drug 196 discovery

Multiancestry genome-wide association study of 520,000 subjects 198 identifies 32 loci associated with stroke and stroke subtypes

Genome for REPositioning drugs

Susceptibility and Severity: Results from Mendelian Randomization and Case-Control 204

Integration of genetically regulated gene 206 expression and pharmacological library provides therapeutic drug candidates

Genomics-driven drug discovery based on disease-209 susceptibility genes

Phenome-wide Mendelian randomization mapping the influence of the 211 plasma proteome on complex diseases

Analysis of genome-wide association data highlights candidates for 213 drug repositioning in psychiatry

Genetic effects on gene expression across human tissues

A Next Generation Connectivity Map: L1000 Platform and the 217 First 1,000,000 Profiles

Analysis of GWAS Data

Biological interpretation of genome-wide association studies using 221 predicted gene functions

Leveraging polygenic enrichments of gene features to predict 223 genes underlying complex traits and diseases

Proteome-wide Mendelian randomization in global biobank meta-225 analysis reveals trans-ancestry drug targets for common diseases

Large-scale cis-and trans-eQTL analyses identify thousands of 227 genetic loci and polygenic scores that regulate blood gene expression

Genomic atlas of the human plasma proteome

Connecting genetic risk to disease end points through the human 232 blood plasma proteome

Mapping of 79 loci for 83 plasma protein biomarkers in 234 cardiovascular disease

Co-regulatory networks of human serum proteins link genetics to 236 disease. Science (80-. )

Genome-wide mapping of plasma protein QTLs identifies putatively 238 causal genes and pathways for cardiovascular disease

A more accurate method for colocalisation analysis allowing for multiple 241 causal variants

Bayesian Test for Colocalisation between Pairs of Genetic 243

Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm

PDGFB, a new candidate plasma biomarker for venous 250 thromboembolism: results from the VEREMA affinity proteomics study

Associations of ApoAI and ApoB-Containing Lipoproteins With AngII-253

Induced Abdominal Aortic Aneurysms in Mice

DrugBank 5.0: a major update to the DrugBank database for 256 2018

Therapeutic Target Database

An Evidence-Based Framework for Evaluating 260

Open Targets Platform: supporting systematic drug-target 263 identification and prioritisation

Cardiac concentric hypertrophy promoted by activated Met receptor is 265 mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib

Mitogen-activated protein kinase kinase 1/2 268 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused 269 by lamin A/C gene mutation

Abelacimab for Prevention of Venous Thromboembolism

Inhalation of urokinase-type plasminogen activator reduces airway 273 remodeling in a murine asthma model

Therapeutic effects of histone deacetylase inhibitors in a murine asthma 276 model

Once-daily mometasone plus indacaterol versus 278 mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately 279 controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, 280 controlled phase 3 study

Masitinib Significantly Decreases the Rate of Asthma Exacerbations 282 in Patients with Severe Asthma Uncontrolled by Oral Corticosteroids: A Phase 3

CC-BY-NC 4.0 International license Multicenter Study. in B93. LATE BREAKING CLINICAL TRIALS IN AIRWAY 284 DISEASES A4210-A4210

Global Biobank Meta-Analysis Initiative: A genome-wide association 287 meta-analysis identifies novel primary open-angle glaucoma loci and shared biology 288 with vascular and cell proliferation mechanisms

Phosphoinositide 3-Kinase in 290 Asthma: Novel Roles and Therapeutic Approaches

Neuroprotection by Sodium Channel Blockade with 293 Phenytoin in an Experimental Model of Glaucoma

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee 296

BindingDB in 2015: A public database for medicinal chemistry, 298 computational chemistry and systems pharmacology

PDGF-CC induces tissue factor expression: role of PDGF receptor 301 α/β

Clinical use of current polygenic risk scores may exacerbate health 303 disparities

Multi-ancestry GWAS for venous thromboembolism identifies 305 novel loci followed by experimental validation

Intrinsic Pathway of Coagulation and Thrombosis

Mapping the proteo-genomic convergence of human diseases

Reconsidering the 311 validity of transcriptome-wide association studies

LocusZoom: regional visualization of genome-wide association 314 scan results

The STRING database in 2011: functional interaction networks of 316 proteins, globally integrated and scored

Orienting the causal relationship between 318 imprecisely measured traits using GWAS summary data

The MR-base platform supports systematic causal inference across 321

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.03.21267280 doi: medRxiv preprint